---
title: "Biocytogen and Whitehawk partner to develop ADCs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292046659.md"
description: "Biocytogen and Whitehawk Therapeutics have partnered to develop bispecific antibody-drug conjugates (BsADCs). Biocytogen will provide up to five bispecific antibodies via its RenLite platform for Whitehawk to evaluate using its ADC linker-payload technology. The deal includes an upfront payment, milestone-based payments, and royalties. If candidates advance, Whitehawk retains global rights. This follows Biocytogen's April 2026 partnership with Sihuan Pharmaceutical."
datetime: "2026-07-08T07:59:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292046659.md)
  - [en](https://longbridge.com/en/news/292046659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292046659.md)
---

# Biocytogen and Whitehawk partner to develop ADCs

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [02315.HK](https://longbridge.com/en/quote/02315.HK.md)
- [WHWK.US](https://longbridge.com/en/quote/WHWK.US.md)
- [688796.CN](https://longbridge.com/en/quote/688796.CN.md)

## Related News & Research

- [Whitehawk Therapeutics posts corporate deck highlighting ADC platform and Phase 1 pipeline progress](https://longbridge.com/en/news/295105838.md)
- [Whitehawk Therapeutics Q2 net loss narrows](https://longbridge.com/en/news/295106344.md)
- [ADC Therapeutics Q2 loss narrows; cuts 17% workforce](https://longbridge.com/en/news/295791965.md)
- [ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomas](https://longbridge.com/en/news/295800995.md)
- [ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA](https://longbridge.com/en/news/295792223.md)